Stay updated on Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed descriptions of a clinical trial involving cabozantinib and paclitaxel for treating recurrent ovarian cancer, while retaining key identifiers and the principal investigator's name.SummaryDifference39%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check87 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.6%
Stay in the know with updates to Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.